The U.S. Food and Drug Administration just approved erenumab-aooe (Aimovig) to prevent migraines in adults. This medication, the first in a new class of drugs that blocks a molecule involved in migraine attacks, is administered via once-monthly self-injections.
In three separate clinical trials comparing Almovig to placebo in people with migraine, the medication reduced the number of days per month that those enrolled in the trial experienced a migraine. In the first study, which involved 955 people with episodic migraine over the course of six months, those taking Almovig averaged one or two fewer migraine days per month compared to those taking a dummy pill. In the second study, which involved 577 people with episodic migraine, those taking the new medication averaged one fewer migraine day per month over three months. In the third study, which involved 667 people with chronic migraine over the course of three months, those treated with the drug averaged two-and-a-half fewer monthly migraine days than those taking a placebo.
Common side effects in clinical trials included pain and inflammation at the injection site and constipation.